Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 0.79 |
| ▸ | ACVR1B | P36896 | 12/20 | 0.62 |
| ▸ | ACVRL1 | P37023 | 10/20 | 0.62 |
| ▸ | ACVR1 | Q04771 | 3/20 | 0.62 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.60 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22270338 | 0.89 | TGFBR1 (0.79) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879386 | 0.84 | TGFBR1 (0.82) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879337 | 0.84 | TGFBR1 (0.66) | TGFBR1ACVR1BACVRL1ACVR1 | |
| SCHEMBL18219797 | 0.83 | TGFBR1 (0.84) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879195 | 0.83 | TGFBR1 (0.84) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16888489 | 0.82 | TGFBR1 (0.55) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16888488 | 0.81 | TGFBR1 (0.58) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL29409536 | 0.80 | TGFBR1 (0.61) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL16879606 | 0.79 | TGFBR1 (1.00) | TGFBR1ACVR1BACVRL1ACVR1BMPR1A | |
| SCHEMBL18219801 | 0.78 | TGFBR1 (0.68) | TGFBR1ACVR1BACVRL1ACVR1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3089971-B1 | COMPOUNDS AND METHODS OF USE | MEDIVATION TECH LLC (US) | 2020-07-29 | — | — | EP | disclosed |